Aurobindo arm TheraNym to invest upto $175 million for new facility

Aurobindo Pharma subsidiary TheraNym Biologics will construct a greenfield project for commissioning a large scale mammalian drug substance manufacturing facility (Unit 2) housing a total of 60 KL bioreactor capacities.

Theranym will invest around $150-175 million for establishing manufacturing facility of mammalian cell culture bioreactors, with an aggregate capacity of 60,000 litres, together with requisite downstream purification infrastructure to produce drug substance. It follows signing of an additional product schedule, to the existing contract manufacturing operations (CMO) agreement, with Merck Sharpe & Dohme Singapore Trading Pte. Ltd., Singapore (MSD).